Jorge Romaguera
About
Jorge Romaguera is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Jorge Romaguera has authored 281 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 240 papers in Pathology and Forensic Medicine, 154 papers in Oncology and 101 papers in Genetics. Recurrent topics in Jorge Romaguera's work include Lymphoma Diagnosis and Treatment (239 papers), Chronic Lymphocytic Leukemia Research (100 papers) and Viral-associated cancers and disorders (93 papers). Jorge Romaguera is often cited by papers focused on Lymphoma Diagnosis and Treatment (239 papers), Chronic Lymphocytic Leukemia Research (100 papers) and Viral-associated cancers and disorders (93 papers). Jorge Romaguera collaborates with scholars based in United States, China and Greece. Jorge Romaguera's co-authors include Fernando Cabanillas, Peter McLaughlin, Fredrick B. Hagemeister, Maria Alma Rodriguez, Anas Younes, Luis Fayad, Barbara Pro, Felipe Samaniego, Michael Wang and F Swan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
In The Last Decade
Jorge Romaguera
276 papers receiving 9.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jorge Romaguera United States | 52 | 7.1k | 5.4k | 3.3k | 1.6k | 1.6k | 281 | 9.8k | ||
| Luis Fayad United States | 50 | 6.3k 0.9× | 5.5k 1.0× | 2.7k 0.8× | 1.3k 0.8× | 1.3k 0.8× | 334 | 9.7k | ||
| Fredrick B. Hagemeister United States | 52 | 6.1k 0.9× | 4.3k 0.8× | 2.7k 0.8× | 1.6k 1.0× | 791 0.5× | 257 | 8.5k | ||
| Franck Morschhauser France | 56 | 8.8k 1.2× | 6.7k 1.2× | 3.7k 1.1× | 1.8k 1.1× | 1.9k 1.2× | 447 | 12.3k | ||
| Myron S. Czuczman United States | 50 | 6.5k 0.9× | 4.6k 0.9× | 3.5k 1.1× | 1.1k 0.6× | 2.0k 1.3× | 241 | 10.4k | ||
| Won Seog Kim South Korea | 48 | 7.1k 1.0× | 6.3k 1.2× | 1.8k 0.5× | 1.4k 0.8× | 1.3k 0.9× | 462 | 10.8k | ||
| Bruce D. Cheson United States | 37 | 5.3k 0.7× | 3.7k 0.7× | 3.0k 0.9× | 1.4k 0.8× | 1.9k 1.2× | 130 | 9.6k | ||
| Francesc Bosch Spain | 48 | 5.6k 0.8× | 3.4k 0.6× | 4.3k 1.3× | 639 0.4× | 2.0k 1.2× | 243 | 8.7k | ||
| Lorenz Trümper Germany | 42 | 3.9k 0.5× | 3.3k 0.6× | 2.1k 0.6× | 668 0.4× | 1.9k 1.2× | 203 | 7.5k | ||
| Sonali M. Smith United States | 40 | 4.2k 0.6× | 3.3k 0.6× | 2.3k 0.7× | 772 0.5× | 1.3k 0.8× | 263 | 6.8k | ||
| Morton Coleman United States | 47 | 4.8k 0.7× | 3.0k 0.6× | 3.3k 1.0× | 815 0.5× | 1.6k 1.0× | 306 | 8.2k |
Countries citing papers authored by Jorge Romaguera
Since
Specialization
Citations
This map shows the geographic impact of Jorge Romaguera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Romaguera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Romaguera more than expected).
Fields of papers citing papers by Jorge Romaguera
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jorge Romaguera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Romaguera. The network helps show where Jorge Romaguera may publish in the future.
Co-authorship network of co-authors of Jorge Romaguera
This figure shows the co-authorship network connecting the top 25 collaborators of Jorge Romaguera. A scholar is included among the top collaborators of Jorge Romaguera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge Romaguera. Jorge Romaguera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jain, Preetesh, Rashmi Kanagal‐Shamanna, Shaojun Zhang, et al.. (2018). Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood. 132(Supplement 1). 4151–4151.
2.
Jain, Preetesh, Jorge Romaguera, Hun Ju Lee, et al.. (2018). Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR ) in patients with relapsed/refractory mantle cell lymphoma (MCL ). British Journal of Haematology. 182(3). 404–411.
3.
Steiner, Raphaël, Jorge Romaguera, & Michael Wang. (2018). Current trials for frontline therapy of mantle cell lymphoma. Journal of Hematology & Oncology. 11(1). 13–13.
4.
Zhang, Han, Zheng Chen, Sattva S. Neelapu, Jorge Romaguera, & Nami McCarty. (2016). Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment. Oncotarget. 7(12). 14350–14365.
5.
Oki, Yasuhiro, Michelle A. Fanale, Jorge Romaguera, et al.. (2015). Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology. 171(4). 463–470.
6.
Cohen, Lorenzo, Ying Guo, Yuhong Zhou, et al.. (2014). Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. Journal of Hematology & Oncology. 7(1). 41–41.
7.
Hagemeister, Fredrick B., Maria Alma Rodriguez, Steven R. Deitcher, et al.. (2013). Long term results of a phase 2 study of vincristine sulfate liposome injection ( M arqibo ® ) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐ H odgkin lymphomas. British Journal of Haematology. 162(5). 631–638.
8.
Hagemeister, Fredrick B., Maria Alma Rodriguez, Steven R. Deitcher, et al.. (2013). Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas. Blood. 122(21). 3033–3033.
9.
Zhang, Liang, Jing Yang, Jianfei Qian, et al.. (2012). Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 120(18). 3783–3792.
10.
Hagemeister, Fredrick B., Peter McLaughlin, Luis Fayad, et al.. (2010). Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL).. Journal of Clinical Oncology. 28(15_suppl). 8078–8078.
11.
Gupta, Sanjay, Jorge Romaguera, Joe Ensor, et al.. (2009). CT‐guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions. Hematological Oncology. 28(2). 75–81.
12.
Wang, Michael, Yasuhiro Oki, Barbara Pro, et al.. (2009). Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology. 27(31). 5213–5218.
13.
Rodriguez, Maria Alma, Fernando Cabanillas, Nam H. Dang, et al.. (2004). Recovery of natural killer cell counts after one course of CHOP chemotherapy is diminished in patients older than 60 compared to patients younger than 60.. Cancer Research. 64. 507–507.
14.
Oki, Yasuhiro, Barbara Pro, Ebrahim S. Delpassand, et al.. (2004). A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).. Blood. 104(11). 2632–2632.
15.
Rodriguez, Maria Alma, Koen van Besien, Fredrick B. Hagemeister, et al.. (2003). Randomized comparison of frontline alternating chemotherapy versus brief induction followed by autologous stem cell transplant for aggressive lymphomas. Blood. 102(11). 40216.
16.
Esmaeli, Bita, James L. Murray, Moloud Ahmadi, et al.. (2002). Immunotherapy for Low-Grade Non-Hodgkin Secondary Lymphoma of the Orbit. Archives of Ophthalmology. 120(9). 1225–1225.
17.
Sarris, A H, Frederick Hagemeister, Jorge Romaguera, et al.. (2000). Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial. Annals of Oncology. 11(1). 69–72.
18.
Rodríguez, José A., Jorge Romaguera, John T. Manning, et al.. (2000). Nasal-Type T/NK Lymphomas: A Clinicopathologic Study of 13 Cases. Leukemia & lymphoma. 39(1-2). 139–144.
19.
Sarris, A H, K. O. Kliche, A. Preti, et al.. (1999). Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Annals of Oncology. 10(4). 433–440.
20.
Seymour, John F., Peter McLaughlin, Lillian M. Fuller, et al.. (1996). High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Annals of Oncology. 7(2). 157–163.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Luis Fayad Breakdown of academic impact, for papers by Fredrick B. Hagemeister Breakdown of academic impact, for papers by Franck Morschhauser Breakdown of academic impact, for papers by Myron S. Czuczman Breakdown of academic impact, for papers by Won Seog Kim Breakdown of academic impact, for papers by Bruce D. Cheson Breakdown of academic impact, for papers by Francesc Bosch Breakdown of academic impact, for papers by Lorenz Trümper Breakdown of academic impact, for papers by Sonali M. Smith Breakdown of academic impact, for papers by Morton Coleman